Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind ...
Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
2d
Hosted on MSNHives vs. Eczema: What's the Difference?Medically reviewed by Brendan Camp, MD Hives and eczema are two of the most common skin disorders. Hives, clinically known as ...
The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...
The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...
L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.
Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...
Apogee Therapeutics develops therapies for inflammatory autoimmune diseases. Find out why I'm bearish on APGE stock.
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...
Dupilumab is suggested for individuals aged 12 years or older and for pediatric patients who are nonresponsive to PPI therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results